A detailed history of Charles Schwab Investment Management Inc transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 747,291 shares of NBIX stock, worth $102 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
747,291
Previous 752,501 0.69%
Holding current value
$102 Million
Previous $104 Million 16.95%
% of portfolio
0.02%
Previous 0.02%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$114.58 - $153.15 $596,961 - $797,911
-5,210 Reduced 0.69%
747,291 $86 Million
Q2 2024

Aug 12, 2024

BUY
$130.86 - $143.19 $3.58 Million - $3.91 Million
27,323 Added 3.77%
752,501 $104 Million
Q1 2024

May 08, 2024

BUY
$130.4 - $143.74 $5 Million - $5.51 Million
38,343 Added 5.58%
725,178 $100 Million
Q4 2023

Feb 06, 2024

BUY
$106.07 - $132.76 $6.74 Million - $8.44 Million
63,568 Added 10.2%
686,835 $90.5 Million
Q3 2023

Nov 08, 2023

BUY
$94.02 - $117.1 $1.72 Million - $2.15 Million
18,334 Added 3.03%
623,267 $70.1 Million
Q2 2023

Aug 09, 2023

BUY
$89.53 - $104.87 $1.84 Million - $2.15 Million
20,541 Added 3.51%
604,933 $57 Million
Q1 2023

May 11, 2023

BUY
$94.11 - $123.02 $1.73 Million - $2.26 Million
18,353 Added 3.24%
584,392 $59.2 Million
Q4 2022

Feb 13, 2023

BUY
$106.72 - $127.06 $2.67 Million - $3.18 Million
25,063 Added 4.63%
566,039 $67.6 Million
Q3 2022

Nov 14, 2022

BUY
$92.03 - $107.81 $733,939 - $859,784
7,975 Added 1.5%
540,976 $57.5 Million
Q2 2022

Aug 15, 2022

BUY
$75.79 - $100.07 $921,000 - $1.22 Million
12,152 Added 2.33%
533,001 $52 Million
Q1 2022

May 13, 2022

BUY
$72.45 - $94.81 $813,903 - $1.07 Million
11,234 Added 2.2%
520,849 $48.8 Million
Q4 2021

Feb 11, 2022

BUY
$79.65 - $106.22 $999,368 - $1.33 Million
12,547 Added 2.52%
509,615 $43.4 Million
Q3 2021

Nov 16, 2021

BUY
$86.18 - $99.03 $1.5 Million - $1.73 Million
17,419 Added 3.63%
497,068 $47.7 Million
Q2 2021

Aug 16, 2021

BUY
$89.43 - $102.27 $1.12 Million - $1.29 Million
12,579 Added 2.69%
479,649 $46.7 Million
Q1 2021

May 17, 2021

SELL
$87.57 - $119.4 $652,484 - $889,649
-7,451 Reduced 1.57%
467,070 $45.4 Million
Q4 2020

Feb 16, 2021

BUY
$86.91 - $108.33 $346,683 - $432,128
3,989 Added 0.85%
474,521 $45.5 Million
Q3 2020

Nov 13, 2020

BUY
$96.16 - $135.15 $774,088 - $1.09 Million
8,050 Added 1.74%
470,532 $45.2 Million
Q2 2020

Aug 14, 2020

BUY
$85.09 - $130.36 $889,445 - $1.36 Million
10,453 Added 2.31%
462,482 $56.4 Million
Q1 2020

May 15, 2020

BUY
$75.11 - $113.76 $792,560 - $1.2 Million
10,552 Added 2.39%
452,029 $39.1 Million
Q4 2019

Feb 07, 2020

BUY
$86.8 - $118.57 $730,856 - $998,359
8,420 Added 1.94%
441,477 $47.5 Million
Q3 2019

Nov 08, 2019

BUY
$83.82 - $101.5 $2.64 Million - $3.2 Million
31,520 Added 7.85%
433,057 $39 Million
Q2 2019

Aug 09, 2019

BUY
$72.24 - $91.27 $1.13 Million - $1.42 Million
15,588 Added 4.04%
401,537 $33.9 Million
Q1 2019

May 14, 2019

BUY
$69.31 - $91.53 $1.84 Million - $2.43 Million
26,503 Added 7.37%
385,949 $34 Million
Q4 2018

Feb 14, 2019

BUY
$68.32 - $124.36 $971,237 - $1.77 Million
14,216 Added 4.12%
359,446 $25.7 Million
Q3 2018

Nov 13, 2018

SELL
$98.88 - $125.85 $12.6 Million - $16 Million
-127,057 Reduced 26.9%
345,230 $42.4 Million
Q2 2018

Aug 08, 2018

BUY
$75.3 - $105.99 $2.47 Million - $3.47 Million
32,769 Added 7.46%
472,287 $46.4 Million
Q1 2018

May 07, 2018

BUY
$75.88 - $92.43 $2.28 Million - $2.77 Million
29,996 Added 7.32%
439,518 $36.5 Million
Q4 2017

Jan 17, 2018

BUY
$58.53 - $77.59 $1.51 Million - $2 Million
25,834 Added 6.73%
409,522 $31.8 Million
Q3 2017

Nov 13, 2017

BUY
$47.97 - $61.28 $18.4 Million - $23.5 Million
383,688
383,688 $23.5 Million

Others Institutions Holding NBIX

About NEUROCRINE BIOSCIENCES INC


  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $13.1B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track Charles Schwab Investment Management Inc Portfolio

Follow Charles Schwab Investment Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.